Personal Consumption Expenditures PCE Definition & Meaning | Economy Term | CSIMarket

Personal Consumption Expenditures PCE

Economy Term

Personal Consumption Expenditures (PCE) refers to the total amount of money spent by consumers on goods and services in a given period. It is a measure of consumer spending, which is a key driver of economic growth.

PCE is calculated by adding up the total amount of money spent by individuals on things like food, clothing, housing, transportation, healthcare, and other goods and services over a defined period of time, typically a quarter or a year. The data is collected by government agencies, like the Bureau of Economic Analysis (BEA) in the United States.

PCE is used extensively in the industry as a measure of consumer spending and economic activity. Consumer spending accounts for around 70% of the US economy, making it a crucial component of the nation*s Gross Domestic Product (GDP) and an important indicator of economic health. PCE data is used by analysts and policymakers to gauge consumer trends, evaluate economic policies, and forecast future economic activity.

Additionally, PCE data is used to track inflation and adjust government programs, such as Social Security benefits and tax rates, to reflect changes in consumer prices. PCE is also an important factor in business decision-making, as companies rely on consumer spending to drive revenue and profitability. By monitoring PCE trends, businesses can make better decisions about product development, marketing strategies, and pricing.




More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P